Uciderm Plus

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uciderm Plus

Here is a quick overview of Uciderm Plus, detailing its fundamental identity and purpose.

Property Description
Active Ingredient Combination of Corticosteroid, Antibiotic, and/or Antifungal agents
Form Topical Cream or Ointment
Pharmacological Class Corticosteroid/Anti-infective combination
Common Use Managing inflammatory skin conditions complicated by infection
Origin Synthetic Pharmaceutical

What Is Uciderm Plus and What Is It For?

Uciderm Plus is a prescription topical pharmaceutical preparation classified as a combination drug used primarily to manage specific inflammatory and infectious skin conditions. Its general therapeutic purpose is to quickly alleviate common symptoms associated with dermatoses, such as intense itching, redness, and swelling, particularly when complicated by secondary microbial growth. This combination formula is clinically recognized for its ability to provide rapid symptomatic relief in conditions involving both inflammation and infection.

The medicine's classification as a corticosteroid/anti-infective combination means it delivers a multi-pronged action directly to the affected skin area. Pharmacological studies support that combining a potent steroid with antimicrobial agents often leads to a faster resolution of symptoms by addressing both the inflammation and the microbial contamination simultaneously. This product is specifically intended for patients requiring a targeted, dual-action approach.


Uciderm Plus: Key Components and Formulation

Uciderm Plus is formulated as a smooth topical cream or ointment containing two or more active pharmaceutical ingredients (APIs). A typical composition includes a potent corticosteroid (e.g., Clobetasol Propionate) for its strong anti-inflammatory effect, paired with an antibiotic (e.g., Gentamicin) and/or an antifungal agent (e.g., Clotrimazole).

These components are typically synthetic compounds manufactured to precise pharmaceutical standards. The combination approach is essential in dermatology, a strategy often highlighted in research as it simplifies treatment for patients dealing with both inflammation and concurrent microbial issues.

Regulatory References

  1. MedlinePlus: Drugs, Herbs and Supplements
  2. PubMed

What side effects are possible with Uciderm Plus?

Possible Side Effects and Safety Information

The safety profile for Uciderm Plus, a topical combination of a potent corticosteroid and anti-infective agents, is officially documented by regulatory authorities (such as the FDA and EMA) and is primarily structured around two categories: local reactions and the potential for systemic absorption.


Local Adverse Reactions and Frequency

Adverse reactions affecting the skin are the most frequently reported. Reactions classified as common in regulatory documentation include burning, stinging, itching (pruritus), and irritation at the application site. Less common reactions can include skin atrophy (thinning), striae (stretch marks), acneiform eruptions, and folliculitis.


Serious Systemic Risk and Duration Dependency

The most significant official safety concern arises from the systemic absorption of the potent corticosteroid component. Serious adverse reactions documented in regulatory labeling include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations resembling Cushing's syndrome.

This risk is explicitly tied to duration and exposure: the potential for systemic effects, including HPA axis suppression and severe skin thinning, increases with prolonged use, application to large body surface areas, or use under occlusive dressings. Additionally, the antibiotic component (e.g., an aminoglycoside) carries a documented, high-level, though rare, potential for ototoxicity or nephrotoxicity if significant systemic absorption occurs.


Population-Specific Safety Notes

The pediatric population is officially noted as being more susceptible to systemic toxicity, including HPA axis suppression and growth retardation, due to a larger skin surface area-to-body mass ratio compared to adults. The official label specifies that particular caution and close monitoring are required in this age group.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Uciderm Plus, which contains a high-potency corticosteroid, is primarily associated with the risk of systemic absorption resulting from prolonged, excessive, or widespread use over large areas of the body. This systemic effect can lead to serious endocrine and metabolic issues.

Documented Overdose Effects

The most significant risks from excessive use relate to the potential for systemic absorption of the corticosteroid component. This may result in:

  • Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression: A reversible condition that impairs the body's natural production of steroids and may lead to glucocorticosteroid insufficiency, especially upon withdrawal of the medication.
  • Cushing's Syndrome: A disorder caused by prolonged exposure to high levels of corticosteroids, characterized by symptoms affecting the body's metabolism and appearance.
  • Hyperglycemia: An increase in blood sugar levels.

Pediatric patients may be more susceptible to systemic toxicity and HPA axis suppression due to their larger skin surface area-to-body weight ratio. Factors that increase the risk of systemic absorption include using the product under occlusive (airtight) dressings or over compromised skin.

When Immediate Medical Help is Required

Emergency medical services must be contacted immediately for a suspected overdose or accidental ingestion.

If the topical medication is accidentally swallowed, call a local Poison Control Center right away. If the affected individual has collapsed or is not breathing, contact emergency services (e.g., 911) without delay, as described in official government regulatory documents.

Therapeutic Uses of Uciderm Plus

Therapeutic Scope: What Uciderm Plus Treats and the Benefits It Provides

This product is commonly used across domains where inflammatory skin conditions are simultaneously complicated by secondary microbial growth, such as bacterial or fungal infections. Applicable indications often include atopic dermatitis, contact dermatitis, and other steroid-responsive dermatoses when presenting with concurrent infection. The combination is applied in addressing symptoms that interfere with daily functioning, encompassing the redness, swelling, itching, and discomfort associated with the primary inflammation, along with the infection caused by certain bacteria.

The medication is applied when supportive symptom management is needed to moderate two distinct types of distress. This dual focus supports the management of both components concurrently, assisting with the management of the acute symptomatic phase.

“The product is designed to provide supportive relief during flares where both acute inflammation and microbial growth are present.”

Focus on Symptom Management: Intense Itching (Pruritus)

The cream is relevant for easing the pronounced symptoms of intense pruritus and swelling, which supports the patient during difficult episodes by easing distress.

Regulatory References

  1. NIH MedlinePlus overview of Neomycin, Polymyxin, Bacitracin, and Hydrocortisone Topical

Eligibility and Restrictions for Use

Who can and cannot use Uciderm Plus?

This eligibility profile is defined by official regulatory documents and restrictions associated with its potent corticosteroid and anti-infective components.

Contraindications and Prohibited Populations

Uciderm Plus is contraindicated in patients with a documented history of hypersensitivity to any of its active or inactive ingredients. Use is absolutely prohibited in individuals with specific primary skin conditions, including rosacea, perioral dermatitis, acne vulgaris, and primary cutaneous infections caused by viruses (such as herpes simplex or varicella) [Source: Official Labeling].

Age and Physiological Restrictions

Population Group Eligibility Status (Regulatory Wording)
Children under 12 years Not Recommended; highly susceptible to systemic effects (HPA axis suppression).
Pregnant Women Restricted Use; use only if the potential benefit outweighs the risk to the fetus.
Nursing Mothers Not Recommended; must use caution, especially if applying to the breast area.

Conditional Use and Limitations

Use is restricted to small, localized areas for short durations. The medication should not be applied to the face, groin, or axillae, and must not be applied under occlusive dressings (airtight bandages) due to the increased risk of systemic absorption [Source: Official Labeling]. Patients with pre-existing conditions like liver failure or diabetes may require additional caution.

What should I know about interactions with other medicines?

Uciderm Plus is a topical combination containing the antibiotic fusidic acid and the corticosteroid betamethasone. The potential for drug interactions is primarily related to the systemic absorption of its active components, which increases with prolonged use, application over large areas, or use under occlusive dressings.

Potential for Pharmacokinetic Interactions

  • Corticosteroid Interactions (Betamethasone): The systemic exposure to betamethasone may be increased when co-administered with strong inhibitors of the Cytochrome P450 3A4 (CYP3A4) enzyme system. These inhibitors (such as ritonavir or cobicistat) can reduce the metabolism of betamethasone, potentially leading to systemic corticosteroid effects like Cushing's syndrome or adrenal suppression, especially in cases of extensive application.
  • Fusidic Acid Interactions: When fusidic acid is absorbed systemically, it may interfere with the metabolism of other drugs. The combination of systemic fusidic acid and HMG-CoA reductase inhibitors (statins) carries a known risk of severe muscle toxicity (rhabdomyolysis), and this restriction is extended as a caution for topical use when significant systemic absorption is anticipated.

Other Specific Interaction Classifications

  • Anticoagulants: Fusidic acid may enhance the effect of coumarin anticoagulants, such as warfarin. Patients using Uciderm Plus, particularly over large or damaged skin areas, should be monitored for signs of increased bleeding risk. International Normalized Ratio (INR) monitoring is typically advised if co-administration occurs.

No formal interaction studies have been conducted for Uciderm Plus itself; therefore, these interaction notes are based on the known pharmacologic profiles and systemic risks of the individual active substances.

Mechanism of Action

How Uciderm Plus Works

The mechanism of action of Uciderm Plus involves a coordinated approach, targeting two distinct biological processes simultaneously: modulating host-driven inflammatory pathways and inhibiting the synthesis of proteins essential for microbial viability.


Modulation of Inflammatory Gene Expression

The corticosteroid component acts on intracellular glucocorticoid receptors, engaging mechanisms that regulate overactive or dysregulated transcriptional processes. This binding complex inhibits the expression of genes responsible for creating key inflammatory mediators (like cytokines and chemokines), influencing the signal transduction sequences that maintain equilibrium and modulating the downstream effects resulting from heightened mediator activity.


Inhibition of Bacterial Protein Synthesis

The antibacterial component works by directly interfering with the bacterial ribosomal machinery, specifically targeting the elongation factor G (EF-G). This action blocks the synthesis of proteins essential for microbial proliferation, supporting the regulation of processes driven by distinct signaling patterns and reducing the proliferative rate of susceptible microorganisms.

Dosage and Administration Information

Administration Scope

Uciderm Plus is a prescription topical pharmaceutical preparation, and its administration is strictly limited to the topical route (external use only). It is explicitly not approved for ophthalmic (eye), oral, or intravaginal application. The standard adult dosing regimen requires applying a thin film of the product to the affected area twice daily.

There are established quantity and duration constraints for use. The total amount applied should not exceed 45 grams per week, which is the defined maximum limit. The treatment course is typically short-term, generally ranging from one to four weeks, depending on the site of application. Use in the groin area, for example, is restricted to a maximum of two weeks. Furthermore, this product is generally not recommended for use in pediatric patients under 17 years of age.

Special Procedural Conditions

A key procedural constraint is the requirement for non-occlusion. The treated skin surface must not be covered, bandaged, or wrapped unless specific instruction is received from a healthcare provider, as covering the area can alter product absorption. Patients must complete the full prescribed course duration, even if visible improvement in the skin condition occurs earlier.


Connection to the Overall Use Protocol

Standard administration guidelines structure the use of Uciderm Plus as a short-term, quantity-limited treatment. The specific constraints on topical route, twice-daily frequency, and maximum weekly dose are established to control both the extent and duration of exposure to the combination agents. This protocol defines the standard methodology for its use in clinical practice.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uciderm Plus

This section provides a factual, non-causal overview of the available research and clinical studies for the class of medicine to which Uciderm Plus belongs, based on its classification as a potent Corticosteroid/Anti-infective combination agent. This information describes what was studied, not what the medicine does for an individual patient.


Research Evidence Overview

The research base for this combination drug class is primarily formed by short-term Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews that evaluate the combination of dual-action topical agents. These studies are used in research exploring how symptoms change over time in patients with inflammatory skin conditions that are also associated with microbial growth. The available research generally focuses on short observation periods and tracks patient experiences using standard clinical and patient-reported scales.


Evidence for Dermatoses Complicated by Microbial Growth

Research on this class of medicine was studied for conditions characterized by fluctuating or episodic manifestations where inflammation and microbial contamination are present concurrently.

Short-term studies report how symptoms evolved in the observed populations, comparing the combination to using the steroid component alone or a vehicle. The findings describe patterns observed in the studies over the short-term follow-up period (1 to 4 weeks), particularly in relation to changes in disease severity and registered changes in patient-reported outcomes describing perceived discomfort.

The follow-up durations were limited, typically lasting only 1 to 4 weeks, therefore, evidence for long-term effects regarding sustained use is not fully established. The evidence quality varies across studies due to differences in the specific anti-infective agents used in the combination formulations.


Studies Focused on Atopic Dermatitis with Infection

Atopic Dermatitis (AD) is a condition frequently used in research to evaluate the dual-action approach of corticosteroid-anti-infective combinations when signs of infection are present. Research explored the effects of the combination in defined AD patient cohorts, including specific cohorts of children.

Trials documented measured changes in AD-specific severity scores across the short-term follow-up period. Studies report how symptoms evolved in the observed populations when the combination was evaluated in patients with clinical evidence of secondary infection. Research highlights changes measured during the study period in symptom intensity.

Limited information for long-term outcomes is available for managing AD over extended periods using this combination class. The sample sizes were modest in some comparison studies, which may affect the ability to draw definitive conclusions across varied patient profiles.


What is Still Uncertain About the Research

Scientific literature and regulatory reviews highlight several areas where research is ongoing or data remain insufficient:

  • Comparative evidence is lacking for the head-to-head comparison of this specific combination against all possible alternative combination therapies.
  • The certainty remains low on the long-term patterns, as follow-up durations were limited in many of the core clinical trials for this drug class.
  • Data for comorbidity-defined groups or pregnant populations remain insufficient. The results apply only to the populations studied and cannot be extrapolated to groups where research is lacking.

Key Studies & References Topical Corticosteroids (StatPearls - NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Uciderm Plus (FAQ)

Q: How quickly can I expect to see a change after starting Uciderm Plus?

A: Official information suggests that improvement for this product class is often noted within a few days of starting treatment. Regulatory guidance advises that a noticeable change should be observed shortly after treatment begins.


Q: What happens if I stop using Uciderm Plus suddenly?

A: Regulatory guidance advises against stopping treatment early, even if the symptoms appear to improve. This is because the antibiotic component is intended to clear the infection fully, and regulatory guidance advises that stopping early may allow the infection to return.


Q: What is the difference between Uciderm Plus cream and Uciderm Plus ointment?

A: The official documentation describes Uciderm Plus as being available in both cream and ointment forms. The cream formulation is described as suitable for lesions that do not require a dressing, while the ointment is often preferred for conditions where a dressing may be used. In general, the ointment form may form a thicker, more protective layer than the cream.


Q: How long are most treatment courses with Uciderm Plus?

A: Regulatory prescribing information states that treatment with Uciderm Plus is typically short-term. The standard duration generally ranges from one to four weeks. Use in specific areas, such as the groin, is usually restricted to a maximum of two weeks.


Q: Does Uciderm Plus interact with any common blood pressure medicines?

A: Formal interaction studies for Uciderm Plus itself have generally not been performed. However, due to minimal systemic absorption when applied correctly, official sources suggest that interactions with systemically administered medicines, such as common blood pressure drugs, are considered minimal.


Q: Does Uciderm Plus interact with oral diabetes medications?

A: Due to the corticosteroid content, official documents state that the glycaemic control of diabetic patients should be monitored with care while undergoing treatment. This caution is advised because corticosteroids, even when applied topically, may have the potential to affect blood sugar levels.


Q: Can the ingredients in Uciderm Plus be absorbed into the bloodstream?

A: Yes, official labeling notes that the potent corticosteroid component of Uciderm Plus has the potential for systemic absorption (entering the bloodstream). This risk increases significantly if the product is used for prolonged periods, applied over large body areas, or used under occlusive (airtight) dressings.


Q: What research is available on Uciderm Plus use in children under 2 years old?

A: Official labeling states the product is not recommended for use in young children. Regulatory documents address the use of dermal steroids in this population, advising that babies and children up to four years should not be treated with dermal steroids for longer than three weeks due to their increased susceptibility to systemic side effects.


Q: What are the potential effects of using Uciderm Plus longer than prescribed?

A: Official warnings state that prolonged topical use may cause local skin damage, such as skin atrophy (thinning). Furthermore, continuous use over extended periods increases the risk of systemic effects, including HPA axis suppression (an effect related to hormone balance) and manifestations resembling Cushing's syndrome due to corticosteroid absorption.


Q: What are the symptoms of using too much Uciderm Plus?

A: If Uciderm Plus is used in excessive amounts, especially over large areas or for more than three weeks, symptoms may arise from the systemic absorption of the corticosteroid. These symptoms could resemble those of Cushing's syndrome or adrenocortical insufficiency (an effect related to hormone balance).


Q: Can Uciderm Plus be used for something like eczema or just fungal issues?

A: According to the official product indications, Uciderm Plus is indicated for managing inflammatory skin conditions, such as dermatitis, that are also infected, or at risk of infection, by certain bacteria. Its purpose is to address both the inflammation and the microbial component simultaneously.


Q: Can Uciderm Plus cause discoloration or changes to skin pigment?

A: Official regulatory documents list changes to skin pigment as potential effects associated with the potent corticosteroid component. These documented changes can include depigmentation (lightening of the skin) and hypertrichosis (excessive hair growth).


Q: Are there any food or drink restrictions while using Uciderm Plus?

A: Regulatory guidance for the active ingredients in Uciderm Plus generally states that users can eat or drink normally while using the cream or ointment. No specific restrictions on food or beverage consumption are documented in the official labeling.


Q: Does Uciderm Plus cause hair loss where it's applied?

A: The official side effect profile of the corticosteroid component lists various skin changes. These can include thinning of the hair or, conversely, hair growth (hypertrichosis) as documented potential skin alterations.


Q: If I miss a dose, what is the official advice on what to do next?

A: Regulatory guidance suggests that if a dose is missed, it should be applied as soon as it is remembered. The user should then continue to use it at the usual time for the remaining applications.


Q: What are the signs that Uciderm Plus is actually working?

A: Signs observed in studies include the lessening of symptoms such as redness, itching, and swelling in the affected area. Official information advises that the user should notice their skin condition improve after just a few days of using the cream.


Q: What are the inactive ingredients in Uciderm Plus?

A: In addition to the active drug components, official documents list inactive ingredients, also known as excipients. These typically include substances such as cetostearyl alcohol, liquid paraffin, and purified water, which are used to form the base of the cream or ointment.


Q: Can I use Uciderm Plus if I have an open cut or wound?

A: General caution is noted against applying the medicine to areas of broken skin, large sores, cuts, or scrapes. Applying Uciderm Plus over large areas of damaged skin can increase the absorption of the ingredients into the bloodstream, thereby increasing the risk of systemic effects.


Q: Does Uciderm Plus have any effect on bacterial skin problems?

A: Yes. The combination product contains an antibiotic component, which is intended for killing germs (bacteria) that cause infections. It is specifically used for inflammatory skin conditions that are infected by bacteria sensitive to the antibiotic ingredient.


Q: Is Uciderm Plus commonly used in veterinary medicine (for pets)?

A: A combination gel containing the same active ingredients is approved by regulatory bodies for the topical treatment of localized, mild, or moderate acute moist dermatitis in dogs. Official approval for this specific use exists in veterinary documents.


Q: What data exists on the long-term safety of Uciderm Plus?

A: Official warnings state that long-term continuous topical therapy should be avoided with this drug class. Regulatory reviews indicate that the core clinical trials had limited follow-up durations, meaning evidence for the long-term effects regarding sustained use is not fully established.


Q: Is it true that Uciderm Plus is only for use on the body and not the scalp?

A: While the combination product is restricted from the face, groin, and armpits, the specific ban on the scalp is not universally documented for all similar products. The potent corticosteroid component (betamethasone) is available in other formulations specifically used to treat scalp problems, suggesting that the limitation is dependent on the specific product formulation prescribed.


Q: Does Uciderm Plus interact with birth control pills?

A: Official regulatory documents generally state that no formal interaction studies have been performed to evaluate the interaction with hormonal contraceptives. However, due to minimal systemic absorption when used correctly, interactions with systemically administered medicinal products are generally considered minimal.


Q: Does Uciderm Plus work immediately or does it need time to build up in the skin?

A: According to official documentation, the user should notice their skin condition improve after just a few days of using the cream. This suggests the product begins to work relatively quickly to reduce symptoms like inflammation and itching.

How should Uciderm Plus be stored and disposed of?

Storage and Disposal for Uciderm Plus Cream

Uciderm Plus cream (fusidic acid and betamethasone valerate) must be stored and handled according to the instructions provided in its official regulatory labeling.

Official Storage Conditions

Storage Requirement Details
Maximum Temperature Do not store above 30°C.
Unopened Shelf-Life 36 months (3 years) in the original container.
Stability After Opening Use the product within 6 months of the first opening.
Child Safety Must be kept out of the sight and reach of children.

Handling and Disposal

The product must be kept in the original aluminum tube as supplied. Any unused or expired Uciderm Plus, including any waste material, must be disposed of in accordance with local pharmaceutical waste requirements. No special hazardous waste classification is typically specified for this topical preparation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uciderm Plus found in:

A-Z Index: